TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05268003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mini-hyper CVD
Description: Given by IV (vein)
Study: NCT05120167

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endocervical liquid-base cytology
Description: Endocervical sample collected by brushing and preserved in a liquid-base.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endocervical cell block
Description: Endocervical sample collected by endocervical brush and preserved in a buffered formalin base for obtaining a cell block and evaluated as histology.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endocervical curettage
Description: Endocervical sample obtained by curettage, preserved in buffered formalin, and evaluated as histology.
Study: NCT05217797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearing glasses (any type)
Description: Participants are asked to wear glasses in public spaces.
Study: NCT05263024

Intervention type: DEVICE
Intervention: atrial appendage clip
Description: During cardiac surgery, atrial fibrillation patients were treated with atrial appendage clipping

Intervention type: DEVICE
Intervention: atrial appendage clip
Description: During cardiac surgery, atrial fibrillation patients were treated with atrial appendage clipping
Study: NCT06448234

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standart supplementation therapy group
Description: Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-guided supplementation therapy group
Description: Participants receive DS prescriptions determined by an AI system, which considers genetic data, metabolic profiles, biochemical markers, and patient history.
Study: NCT06548529

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HER2 expression of PET imaging
Description: Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in bladder cancer patients treated with ADC
Study: NCT06224387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTS2190 capsules
Description: 4-6 dose groups are pre-specified in Dose Escalation,and 4 arms in Dose Expansion.
Study: NCT05649605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone treatment
Description: Cross-sex hormone therapy consisting of intramuscular injection of testosterone undecanoate 250mg/ml. 4ml (total dosage of 1000mg) administered by trained nurse in the gluteal region at visit 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Saline solution. Intramuscular injection of physiological saline solution. 4ml administered by trained nurse in the gluteal region at visit 1.
Study: NCT06029959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: Eligible participants with a diagnosis of OSA will be set up with autotitrating CPAP by the study's sleep technologist. The CPAP device includes an auto-titrator that adjusts the delivered pressure between 5 to 15 cm of water to eliminate obstructive events.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPAP technical support intervention
Description: SCOUTS 3 sleep technologists (ST) will make mask type/size or device adjustments, as needed, and provide training to participants and CPAP partners to improve skills involved with mask placement and device maintenance. For participants with non-acceptance of CPAP over the first night, a standardized desensitization program will be implemented. Persistent problems with CPAP use or mask fit, or any high residual respiratory events will be discussed between the sleep technologist and the study's board-certified sleep medicine physician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Description: In-person Motivational Enhancement Therapy (MET) sessions by a trained sleep coach will occur within a week of starting CPAP and, with permission, conducted with a CPAP partner, when available. The MET session recordings will be uploaded into the HIPAA compliant Lyssn platform for evaluation, including feedback to the sleep coach. The goal will be 5 total MET sessions, either in-person or by phone, spanning the inpatient and then outpatient settings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health intervention
Description: Study participants will be assisted in registering for and trained on the ResMed myAir app. Participants will also receive mobile health messages based on Self-Determination Theory.
Study: NCT05668767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib Durvalizumab EP/EC
Description: Etoposide: total 100 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w Cisplatin: total 75 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w; or Carboplatin: AUC 5-6, intravenous infusion, administered on day 1 of each treatment cycle, q3w
Study: NCT06020404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supine position
Description: At the end of the PEEP trial (i.e. at PEEP 5 cmH2O), patients will lay in the supine position for 15 minutes arterial blood gases will be performed and then a one-breath derecruitment maneuver (5-second exhalation, respiratory rate \< 8 bpm) from PEEP 5 cmH2O to 0 cmH2O will be conducted to assess baseline functional residual capacity (FRC), defined as the EELI measured at 0 PEEP.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supine position
Description: At the end of the PEEP trial (i.e. at PEEP 5 cmH2O), patients will lay in the supine position for 15 minutes arterial blood gases will be performed and then a one-breath derecruitment maneuver (5-second exhalation, respiratory rate \< 8 bpm) from PEEP 5 cmH2O to 0 cmH2O will be conducted to assess baseline functional residual capacity (FRC), defined as the EELI measured at 0 PEEP.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prone position
Description: After the supine step, each enrolled patient will be placed in the prone position for 1 hour.~For safety reasons, enteral feeding will be interrupted 30 minutes before prone positioning and re-established after the study ending.~During pronation FiO2 will be increased up to 80% and then gradually decreased to the baseline value within the first 30 minutes of prone positioning. After 30 minutes of PEEP 12 cmH2O (provided that plateau and driving pressures did not exceed 30 cmH2O and 15 cmH2O, respectively) to stabilize lung volumes, the same measurements applied for the supine step will be performed. Any further modifications in the MV settings will be discouraged over the entire course of the study; nonetheless, if needed to achieve the SpO2 target, an increase in FiO2 will be allowed and recorded.~In case of sudden worsening of the oxygenation impairment or haemodynamic, 100% FiO2 will be set, and the patient will be promptly positioned in the supine semi-recumbent position.
Study: NCT05670808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine injection
Description: Different doses on epinephrine will be administered to study arms to observe its impact on blood loss

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine injection
Description: Different doses on epinephrine will be administered to study arms to observe its impact on blood loss
Study: NCT06020404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prone position
Description: After the supine step, each enrolled patient will be placed in the prone position for 1 hour.~For safety reasons, enteral feeding will be interrupted 30 minutes before prone positioning and re-established after the study ending.~During pronation FiO2 will be increased up to 80% and then gradually decreased to the baseline value within the first 30 minutes of prone positioning. After 30 minutes of PEEP 12 cmH2O (provided that plateau and driving pressures did not exceed 30 cmH2O and 15 cmH2O, respectively) to stabilize lung volumes, the same measurements applied for the supine step will be performed. Any further modifications in the MV settings will be discouraged over the entire course of the study; nonetheless, if needed to achieve the SpO2 target, an increase in FiO2 will be allowed and recorded.~In case of sudden worsening of the oxygenation impairment or haemodynamic, 100% FiO2 will be set, and the patient will be promptly positioned in the supine semi-recumbent position.
Study: NCT04541017

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT or diagnostic CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT or diagnostic CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mogamulizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch Biopsy
Description: Undergo skin punch biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Punch Biopsy
Description: Undergo skin punch biopsy
Study: NCT05326139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: TA-soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Isotonic saline -soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
Study: NCT05115383

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VO2 Max test
Description: The participant will be equipped with a vo2 mask or mouthpiece. They will get on the bike and begin with a 5 minute warmup ranging from 30-100 watts. After the warm up there will be a 15-30 watt increase every minute in the cadence that the participant is required to maintain. Once the participant has decided to stop pedalling, the participants mask will be removed to ensure they are feeling well. They will allowed to continue pedaling at their own pace for a cool down for up to two minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VO2 Max test
Description: The participant will be equipped with a vo2 mask or mouthpiece. They will get on the bike and begin with a 5 minute warmup ranging from 30-100 watts. After the warm up there will be a 15-30 watt increase every minute in the cadence that the participant is required to maintain. Once the participant has decided to stop pedalling, the participants mask will be removed to ensure they are feeling well. They will allowed to continue pedaling at their own pace for a cool down for up to two minutes.
Study: NCT05575648

Intervention type: OTHER
Group type: OTHER
Intervention: 10 meter walk test
Description: To assess the dual task performance of children 10 meter walk test will be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10 meter walk test
Description: To assess the dual task performance of children 10 meter walk test will be used.
Study: NCT05827497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 MG
Description: baricitinib 2 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate 25mg
Description: 25mg daily
Study: NCT05279521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation exercise
Description: The lung rehabilitation exercise is divided into three parts: upper and lower limb muscle strength, endurance training and breathing training skills. It lasts for eight weeks of exercise training, and the exercise frequency is: three times a week.
Study: NCT05315271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-ketamine injection
Description: 20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus ketamine (1 mg/kg) with maximum dose 100mg ; the total volume is 30 ml with the infusion of 100 ml normal saline at a rate of 100ml/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine injection with intravenous ketamine infusion
Description: 20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus 10 ml saline ; the total volume is 30 ml with the infusion of ketamine 0.15 mg/kg added to 100 ml normal saline and will be infused at a rate of 100 ml/h, which will be stopped 5 min before the end of surgery.
Study: NCT06010394

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: ultrasound electrotherapy cold applications

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: ultrasound electrotherapy cold applications

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: ultrasound electrotherapy cold applications

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises for the knee area
Description: range of motion exercises strengthening exercises exercises to reduce edema

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: payment oriented massage
Description: 10 / 15-minute massage treatments to reduce payment
Study: NCT05927610

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lumber Puncture
Description: During the lumbar puncture/LP, 20cc will be collected per standard practice in adult patients. LP will be performed either at bedside or under interventional radiology (IR) guidance (due to patient anatomy).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lumber Puncture
Description: During the lumbar puncture/LP, 20cc will be collected per standard practice in adult patients. LP will be performed either at bedside or under interventional radiology (IR) guidance (due to patient anatomy).
Study: NCT04953767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue light therapy
Description: Blue light therapy has been proved its efficacy and safety is treatment circadian rhythm disorder as well as other diseases.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: White light
Description: White light is used as sham control.
Study: NCT05181007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefanamic Acid
Description: mefanamic acid once every 6 hours on Day 4 and Day 5, Ciprofol on Day 1 and Day 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate
Description: valproate once daily on Day 4 to Day 8, Ciprofol on Day 1 and Day 8
Study: NCT04723433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen gas -Conservative
Description: Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) between 90% and 94%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen gas -Liberal
Description: Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) higher than 96%.
Study: NCT06027281

Intervention type: OTHER
Intervention: Hamilton depression rating scale (HDRS)
Description: Hamilton depression scale (HDRS) is the most commonly used instrument for assessing symptoms of depression.

Intervention type: OTHER
Intervention: Hamilton depression rating scale (HDRS)
Description: Hamilton depression scale (HDRS) is the most commonly used instrument for assessing symptoms of depression.

Intervention type: OTHER
Intervention: Hamilton anxiety rating scale (HARS)
Description: Hamilton anxiety rating scale (HARS) is a 14-item clinician-rated measure of the severity of perceived anxiety symptoms.

Intervention type: OTHER
Intervention: Hamilton anxiety rating scale (HARS)
Description: Hamilton anxiety rating scale (HARS) is a 14-item clinician-rated measure of the severity of perceived anxiety symptoms.

Intervention type: OTHER
Intervention: Mini international neuropsychiatric interview (MINI)
Description: The Mini International Neuropsychiatric Interview (MINI) was designed as a brief structured diagnostic interview for the major psychiatric disorders in DSM-III-R, DSM-IV and DSM-5 and ICD-10.

Intervention type: OTHER
Intervention: Mini international neuropsychiatric interview (MINI)
Description: The Mini International Neuropsychiatric Interview (MINI) was designed as a brief structured diagnostic interview for the major psychiatric disorders in DSM-III-R, DSM-IV and DSM-5 and ICD-10.

Intervention type: OTHER
Intervention: Minnesota Multiphasic personality Inventory (MMPI)
Description: The Minnesota Multiphasic Personality Inventory (MMPI) is used to assess personality traits and psychopathology.

Intervention type: OTHER
Intervention: Minnesota Multiphasic personality Inventory (MMPI)
Description: The Minnesota Multiphasic Personality Inventory (MMPI) is used to assess personality traits and psychopathology.

Intervention type: OTHER
Intervention: The Symptom Check-List-90-R (SCL-90-R)
Description: The Symptom Check-List-90-R (SCL-90-R) is a widely used psychological status symptom inventory.

Intervention type: OTHER
Intervention: The Symptom Check-List-90-R (SCL-90-R)
Description: The Symptom Check-List-90-R (SCL-90-R) is a widely used psychological status symptom inventory.
Study: NCT05656430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioral Therapy
Description: Intervention based on cognitive behavioural therapy principles and adapted to the coronavirus pandemic situation. The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
Study: NCT05670808

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epinephrine injection
Description: Different doses on epinephrine will be administered to study arms to observe its impact on blood loss
Study: NCT06027281

Intervention type: OTHER
Intervention: Socioeconomic scale (A.El Gilany, A.El Wehady and M.El Wasify)
Description: An Arabic version of the socioeconomic scale consisted of four dimensions, namely, level of education, employment, total family monthly income, and lifestyle of the family.

Intervention type: OTHER
Intervention: Socioeconomic scale (A.El Gilany, A.El Wehady and M.El Wasify)
Description: An Arabic version of the socioeconomic scale consisted of four dimensions, namely, level of education, employment, total family monthly income, and lifestyle of the family.

Intervention type: OTHER
Intervention: The female sexual function index (FSFI)
Description: The female sexual function index is a brief multidimensional scale for assessing sexual function in women.

Intervention type: OTHER
Intervention: The female sexual function index (FSFI)
Description: The female sexual function index is a brief multidimensional scale for assessing sexual function in women.
Study: NCT06051058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Transitions App
Description: Patients in the intervention arm will be randomized to receive the Care Transitions App and utilize it to support their care transition care plan for multiple chronic conditions.
Study: NCT05355636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fertility Management Counseling
Description: counseling
Study: NCT04595487

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left ventricular septal pacing
Description: In the LVSP group, instead of placing the standard RV lead, the commercially available 3830 Select Secure (Medtronic, Minneapolis, USA) lead is introduced via standard transvenous approach and positioned against the right ventricular side of the IVS by using the commercially available non-deflectable septal delivery sheath (C315, Medtronic, Minneapolis, USA) under fluoroscopic guidance. Subsequently this pacing lead is advanced/screwed through the interventricular septum until the left ventricular septum is reached. Accurate lead position at the left ventricular septum will be determined anatomically using fluoroscopy, and electrically by evaluating local electrograms and changes in paced electrocardiogram morphology.~In case of unsuccessful lead positioning in the left ventricular septum, the Select Secure lead may be placed at the His bundle region (natural conduction system of the heart) or in the right ventricle according to the physician's discretion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular pacing
Description: In the RVP group, the ventricular pacing lead is positioned in the right ventricle.
Study: NCT05709821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM60
Description: IMM60, every 3 weeks for up to 6 cycles, intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM60
Description: IMM60, every 3 weeks for up to 6 cycles, intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM60
Description: IMM60, every 3 weeks for up to 6 cycles, intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM60
Description: IMM60, every 3 weeks for up to 6 cycles, intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM60
Description: IMM60, every 3 weeks for up to 6 cycles, intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200 mg, every 3 weeks for up to 35 cycles or approximately 2 years, intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200 mg, every 3 weeks for up to 35 cycles or approximately 2 years, intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200 mg, every 3 weeks for up to 35 cycles or approximately 2 years, intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab, 200 mg, every 3 weeks for up to 35 cycles or approximately 2 years, intravenous (IV) infusion